Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Clin Exp Allergy ; 47(11): 1456-1467, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28703865

RESUMO

BACKGROUND: Atopic dermatitis (AD), psoriasis (PS), and contact dermatitis (CD) are common skin diseases, characterized by barrier disruption and systemic inflammation, with unique epidermal signatures and common inflammatory pathways identified by transcriptomic profiling. This study profiled proteomic signatures in serum from subjects with AD, PS, and CD compared with healthy controls (HC). OBJECTIVE: Identify unique proteomic signatures to distinguish between inflammatory diseases with similar epidermal disruption and overlapping epithelial inflammation. METHODS: Sera from 20 subjects with moderate to severe AD, 10 subjects with CD, 12 subjects with moderate to severe PS, 10 subjects with both AD and CD, and 10 HC with no history of skin disease was analysed using high-throughput proteomic analysis that detects expression of 1129 protein targets. Protein expression was compared between disease and HC, and across diseases for statistical significance (fold change≥1.5 and false discovery rate≤0.05), to identify unique proteomic signatures for each disease. RESULTS: Complement C5A anaphylatoxin (C5A), lipopolysaccharide binding protein (LBP), C-reactive protein (CRP), ILT-4, C-C motif ligand 18 (PARC), and sialic acid-binding Ig-like lectin 14 (SIG14) were significantly modulated in all three diseases compared with HC. We identified unique signatures for AD (Immunoglobulin E (IgE), thymus- and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC)), CD (10 proteins), and PS (kynureninase (KYNU)). Proteomic profiling in subjects with both AD and CD identified additional dysregulated proteins compared with subjects with either condition alone, indicating an exacerbated inflammation reaction. CONCLUSIONS AND CLINICAL RELEVANCE: Unique sera proteomic signatures may distinguish between inflammatory skin diseases despite similar epidermal barrier disruption and epithelial inflammation. This may provide insight into disease pathogenesis, diagnosis, and therapeutic intervention in difficult-to-treat subjects.


Assuntos
Dermatite Atópica/imunologia , Dermatite Atópica/metabolismo , Proteoma , Proteômica , Dermatopatias/metabolismo , Estudos de Casos e Controles , Análise por Conglomerados , Dermatite de Contato/imunologia , Dermatite de Contato/metabolismo , Feminino , Humanos , Imunoglobulina E/sangue , Imunoglobulina E/imunologia , Mediadores da Inflamação/sangue , Mediadores da Inflamação/metabolismo , Masculino , Proteômica/métodos , Dermatopatias/etiologia
2.
Int J Cancer ; 81(3): 451-8, 1999 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-10209961

RESUMO

Basic fibroblast growth factor (FGF2) has potent mitogenic and angiogenic activities that have been implicated in tumor development and malignant progression. The biological effects of FGF2 and other members of the FGF ligand family are mediated by 4 transmembrane tyrosine kinase receptors (FGFRs). To better understand the roles of FGFRs in cancer, the expression of FGF2 and each of the 4 FGFRs was assessed by RNase protection analysis of 60 human tumor cell lines, representing 9 tumor types. Expression of at least one FGFR isoform was detected in 90% and FGF2 mRNA in 35% of the cell lines. Our comprehensive analysis of FGF2 and FGFR expression in human tumor cell lines provides evidence that FGF signaling pathways are active in a majority of human tumor cell lines, and lends support to the development of anti-tumor strategies that target FGFRs.


Assuntos
Fator 2 de Crescimento de Fibroblastos/análise , Neoplasias/metabolismo , Receptores de Fatores de Crescimento de Fibroblastos/análise , Fator 2 de Crescimento de Fibroblastos/genética , Humanos , RNA Mensageiro/análise , Receptores de Fatores de Crescimento de Fibroblastos/genética , Ribonucleases/farmacologia , Células Tumorais Cultivadas
3.
Mol Cell Neurosci ; 17(4): 706-16, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11312606

RESUMO

We show that when gene-activated matrices (GAM) are placed between the proximal and distal stumps of severed rat optic nerves, DNA is retained within the GAM, promoting sustained transgene expression in the optic nerve, in the GAM itself, and, more importantly, in axotomized retinal ganglion cells (RGC). Plasmids that encode basic fibroblast growth factor (FGF2), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT3) promote sustained survival of RGC for over 3 months after the initial injury. These findings suggest that immobilized DNA implanted into a CNS lesion will be delivered by axon terminal uptake and retrograde transport to axotomized neurons. GAM may therefore be a useful agent for promoting sustained neuron survival and axon regeneration. Whether further optimization of the matrices, plasmids, promoters, and genes present in the GAM will promote even more survival or, alternatively, axon regeneration remains to be determined.


Assuntos
Fator 2 de Crescimento de Fibroblastos/genética , Regulação da Expressão Gênica/fisiologia , Terapia Genética/métodos , Traumatismos do Nervo Óptico/terapia , Nervo Óptico/fisiologia , Animais , Axotomia , Fator Neurotrófico Derivado do Encéfalo/genética , Linhagem Celular , Sobrevivência Celular/fisiologia , Cricetinae , Feminino , Rim/citologia , Neurotrofina 3/genética , Nervo Óptico/citologia , Plasmídeos , Ratos , Ratos Wistar , Células Ganglionares da Retina/citologia , Células Ganglionares da Retina/fisiologia , Transfecção/métodos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa